Geron Corp (GERN): Net Income
-$83.50M
Year ended 2025-12-31
-$67.61M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$83.50M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$174.57M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$184.13M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$141.90M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$116.11M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$75.62M | n/m | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | -$68.55M | n/m | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | -$27.02M | n/m | 2021-03-11, From 2018-01-01 |
| 2017-12-31 | -$27.92M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$29.54M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $46.0K | n/m | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | -$35.67M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$38.38M | n/m | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | -$68.88M | n/m | 2015-03-11, From 2012-01-01 |
| 2011-12-31 | -$96.85M | n/m | 2014-03-17, From 2011-01-01 |
| 2010-12-31 | -$111.38M | n/m | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | -$70.18M | n/a | 2012-03-07, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | -$83.50M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$74.90M | n/m |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | -$167.79M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$204.63M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$48.88M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $37.03M | n/m |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | -$25.55M | n/m |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | -$162.45M | n/m |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | -$162.34M | n/m |
Compare GERN, LAB, EWTX, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗